BPC-157 vs TB-500: what the evidence actually says
Preview text: BPC-157 vs TB-500 | Midshire Labs 96 What the first head-to-head study and the FDA’s 2026…
Using this email in an article? Credit: Regen Peptides email via They Sent It, with a link to this page. Full-size image
Use this example
- Subject
- BPC-157 vs TB-500: what the evidence actually says
- Preview text
- BPC-157 vs TB-500 | Midshire Labs 96 What the first head-to-head study and the FDA’s 2026…
- From
- support@
midshirelabs.co.uk - Brand
- Regen Peptides
- ESP
- Klaviyo
- Sent
- Wed Nov 11, 2026, 10:08 AM ET
- Size
- 41 KB
- Images
- 8
- Links
- 21, 8 of them buttons
- Subject length
- 50 characters
Against Regen Peptides's usual
Sent in the 10 AM hour, which holds 14% of its emails; 14% arrive in the 4 AM hour. The subject is 50 characters; its average is 40.
Sent just before and after
| Nov 11, 2026 10:08 AM | BPC-157 vs TB-500: what the evidence actually says (this email) | |
| Oct 21, 2026 7:02 AM | Why every Midshire Labs product is third-party tested | |
| Oct 15, 2026 7:00 AM | What 50 customer reviews say about Midshire Labs | |
| Oct 8, 2026 10:00 AM | BPC-157 vs. TB-500 vs. KPV: three peptides, three different jobs | |
| Oct 2, 2026 1:02 PM | Why do tendons take so long to heal? | |
| Aug 28, 2026 1:05 PM | Don't miss your 10% off | |
| Aug 21, 2026 9:04 AM | A message, from us to you. |
More from Regen Peptides
All Regen Peptides emailsWhat 50 customer reviews say about Midshire Labs
Oct 15, 2026 7:00 AM
Aug 28, 2026 1:05 PM